Business Daily from THE HINDU group of publications
Saturday, Aug 05, 2006

Cross Currency

Group Sites

Corporate - Regulatory Bodies & Rulings
Get Latest BSE Quote
Ranbaxy gets USFDA nod for Risperidone

Our Bureau

New Delhi, Aug. 4

Ranbaxy Laboratories Ltd announced on Friday that it has received tentative approval from the US Food and Drug Administration (USFDA) to manufacture and market Risperidone oral solution (1 mg/mL).

Risperdal (risperidone) is indicated for the treatment of schizophrenia.

The total annual market sales for risperidone oral solution were at $66 million. "We are pleased to receive this tentative approval for Risperidone oral solution.

This product represents a future opportunity for Ranbaxy and will be launched following final approval from the USFDA," Mr Jim Meehan, Vice-President of Sales and Marketing for Ranbaxy Pharmaceuticals Inc, said.

Ranbaxy Pharmaceuticals Inc is a wholly owned subsidiary of Ranbaxy Laboratories Ltd. It is engaged in the sale and distribution of generic and branded prescription products in the US healthcare system.

More Stories on : Regulatory Bodies & Rulings | Pharmaceuticals | Ranbaxy Laboratories Ltd

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Stempeutics set for first stem cell trials

Punjab Tractors moves CLB on Sumitomo issue
K.K. Birla suit hearing on August 21
NHPC pays Rs 223-cr dividend to Govt
Rama Newsprint reduces equity capital base
SABMiller in deal to buy Foster's India for $120 m
Dishman spreads wings in Europe
GM's new unit to have annual capacity of 1.4 lakh units
IOC to go solo on Paradip refinery project
Khaitan Electricals to invest Rs 50 cr in Uttaranchal unit
Lemon Tree hotel in Chennai by 2007-end
Ranbaxy gets USFDA nod for Risperidone
Tata Steel staff to get Rs 100-cr bonus
Syngenta, Super Spinning in pact for cotton project
Corporate social conscience
Ecology losing to corporates in a big way
NTPC Foundation gesture to disabled
Patel Engg plans to venture into hydel power generation
Ruchi Soya forays into soap segment
BPCL's interest payout may rise
Jhagadia to up capacity utilisation
Less growth at the bottom of the pyramid

The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright 2006, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line